Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704130 · ClinicalTrials.gov registry record · NA
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02704130 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants.
The verdict
NCT02704130, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, prospective RCT to study the effectiveness of TACE and MWA combination therapy with MWA monotherapy for the treatment of early HCC. Primary outcome is 2-year intrahepatic disease-free survival.
Interventions
- PROCEDURE Microwave Ablation
- DEVICE Transarterial embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704130
The ClinicalTrials.gov registry entry for NCT02704130 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Microwave Ablation is the first listed.
NCT02704130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02704130 about?
NCT02704130 is a clinical study titled "TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma". This is a single-center, prospective RCT to study the effectiveness of TACE and MWA combination therapy with MWA monotherapy for the treatment of early HCC. Primary outcome is 2-year intrahepatic disease-free survival.
What is the current status of trial NCT02704130?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2016-03. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02704130?
The interventions under investigation include: Microwave Ablation (PROCEDURE), Transarterial embolization (DEVICE).
Who is sponsoring clinical trial NCT02704130?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.